Cour raises $105m to develop autoimmune, inflammatory disease therapies
The funds will be used to advance the development of Cour’s Myasthenia Gravis and Type 1 Diabetes product…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Jan 24
The funds will be used to advance the development of Cour’s Myasthenia Gravis and Type 1 Diabetes product…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
Gilead has also made a $320m equity investment in Arcus and appointed its chief commercial officer Johanna Mercier…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
Through the acquisition, Roche gains access to Carmot's comprehensive research and development (R&D) portfolio, encompassing both clinical and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
Synthekine to receive $40 million upfront payment and eligible to receive milestones, in addition to tiered royalties on…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Jan 24
The FDA approval, which expands Dupixent’s initial approval granted in May 2022, for the treatment of EoE in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Jan 24
The integrated business will now serve those with severe diseases, including those caused by genetics, where there is…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Jan 24
Inhibrx shareholders will receive $30 per share in cash, a CVR that can be exchanged for $5, plus…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Jan 24
Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Jan 24
NS-229 is a potent and selective Janus kinase (JAK) 1 inhibitor, being developed to treat EGPA by restraining…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Jan 24
The fast track status follows the recent Investigational New Drug (IND) clearance for the candidate for use in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates